These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6179159)

  • 41. Combination chemotherapy for the 9L rat brain tumor model system.
    Vats TS; Kimler BF; Henderson SD; Morantz RA
    Cancer Treat Rep; 1982 Mar; 66(3):575-9. PubMed ID: 6174232
    [No Abstract]   [Full Text] [Related]  

  • 42. Pingyangmycin shows no inhibition on the restoration of depressed hemopoiesis and immune function in mice treated with cyclophosphamide.
    Zhang H; Zhen YS
    Proc Chin Acad Med Sci Peking Union Med Coll; 1987; 2(4):202-6. PubMed ID: 2453877
    [No Abstract]   [Full Text] [Related]  

  • 43. Reduced antitumor and immune-adjuvant activities of the sub-cellular fractions from Group A Streptococcus.
    Ryoyama K; Natsuume-Sakai S; Hirota H; Koshimura S
    Jpn J Exp Med; 1981 Dec; 51(6):335-44. PubMed ID: 7040746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Randomized controlled study on the effect of adjuvant immunotherapy with OK-432 on malignant gliomas].
    Shibata S; Mori K; Moriyama T; Tanaka K; Moroki J
    Neurol Med Chir (Tokyo); 1985 Oct; 25(10):832-6. PubMed ID: 2417136
    [No Abstract]   [Full Text] [Related]  

  • 45. [New direction in immunochemotherapy of cancer].
    Nitta K
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1117-28. PubMed ID: 6191674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Chemotherapy of urothelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432].
    Fujihiro S; Takeuchi T; Fujimoto Y; Okano M; Horie M; Kanematsu M; Kuriyama M; Ban Y; Nishiura T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):427-32. PubMed ID: 6200077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols].
    Płuzańska A; Krykowski E; Robak T; Oliskiewicz W; Polkowska E; Dowgier I; Hyjek E
    Pol Tyg Lek; 1982 Sep; 37(36):1049-53. PubMed ID: 6189105
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
    Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
    Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
    [No Abstract]   [Full Text] [Related]  

  • 49. Enhanced resistance to Pseudomonas aeruginosa infection in mice pretreated with OK-432.
    Saito H; Watanabe T; Tomioka H; Sato K; Kitagawa T
    Hiroshima J Med Sci; 1983 Jun; 32(2):235-9. PubMed ID: 6618904
    [No Abstract]   [Full Text] [Related]  

  • 50. [Early diagnosis and effective treatment of ovarian cancer].
    Sawada M; Matsui Y; Okudaira Y
    Gan To Kagaku Ryoho; 1983 May; 10(5):1251-8. PubMed ID: 6191676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Possible clinical application of immunochemotherapy experimented in animals].
    Hosokawa M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):811-6. PubMed ID: 10897206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Scheduled and unscheduled combination chemotherapy in the treatment of squamous cell lung cancer (cyclophosphamide, adriamycin, vincristine and bleomycin, with and without cis-platinum).
    Jones DH; Bleehen NM; Grant RM; Plowman PN; Roberts JT; Sikora K; Watson JV; Wiltshire CR
    Anticancer Res; 1983; 3(4):235-8. PubMed ID: 6192751
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Chemotherapy of advanced breast cancer--actual results ].
    Matthes ML; Lenk H; Gürtler R; Tanneberger S
    Arch Geschwulstforsch; 1982 May; 52(3):241-6. PubMed ID: 6812538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experimental studies on the enhancing effects of the combined therapy with tegafur and cytochrome C].
    Ishibashi S
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):1987-92. PubMed ID: 6311113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Long-term responders of non-Hodgkin's lymphoma: patients treated with combination chemotherapy].
    Nishihara R; Ohnoshi T; Oka A; Hayashi K; Sato M; Ueoka H; Yasuoka M; Sando Y; Kimura I
    Rinsho Ketsueki; 1982 Aug; 23(8):1192-7. PubMed ID: 6183469
    [No Abstract]   [Full Text] [Related]  

  • 56. Role of urokinase-type plasminogen activator in local immunotherapy.
    Takeda T; Ito Y; Wakasugi E; Kobayashi T; Monden M
    Oncol Rep; 1998; 5(2):329-33. PubMed ID: 9468551
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of biological response modifiers in vitro.
    Salmon SE
    J Biol Response Mod; 1983; 2(3):207-9. PubMed ID: 6196452
    [No Abstract]   [Full Text] [Related]  

  • 58. Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin.
    Miller RA; Woodburn KW; Fan Q; Lee I; Miles D; Duran G; Sikic B; Magda D
    Clin Cancer Res; 2001 Oct; 7(10):3215-21. PubMed ID: 11595717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ADP-ribosylation, DNA repair, cell differentiation and cancer.
    Shall S
    Princess Takamatsu Symp; 1983; 13():3-25. PubMed ID: 6317641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bleomycins.
    Lazo JS; Sebti SM
    Cancer Chemother Biol Response Modif; 1993; 14():37-44. PubMed ID: 7508730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.